Carfilzomib

December 10, 2012
Image of Carfilzomib

Carfilzomib, a selective proteasome inhibitor, is marketed by Onyx Pharmaceuticals under the name Kyprolis. FDA approved the epoxomicin derivative in July 2012 for treating patients with relapsed, refractory multiple myeloma. Work by C. M. Crews and co-workers at Yale University led directly to the development of carfilzomib.

MOTW update

Carfilzomib is a selective proteasome inhibitor that is used to treat patients with relapsed, refractory multiple myeloma. But recently, data analysis of 24 clinical trials on carfilzomib revealed high incidence of adverse cardiac events, many of which were severe or life-threatening.

Chemical Abstract Service - a division of ACS

Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.

Molecule of the Week needs your suggestions!

If your favorite molecule is not in our archive, please send an email to motw@acs.org. The molecule can be notable for its current or historical importance or for any quirky reason. Thank you!

Stay Ahead of the Chemistry Curve

Learn how ACS can help you stay ahead in the world of chemistry.